Pediatric idiopathic pulmonary hemosiderosis (IPH) is a lung alveolar capillary hemorrhagic disease that often recurs, characterized by the accumulation of large amounts of iron-laden hemoglobin in the lungs. Lack of awareness or insufficient understanding of the condition can delay diagnosis, affecting the child’s lung fibrosis process and prognosis. Currently, there is no specific treatment method, with the primary therapy being the use of adrenal cortical hormones, maintained for 1 to 2 years, with early discontinuation potentially leading to recurrence.